2-methyl-hexahydro-benzo[1,3]dioxole | 61335-43-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧戊环
• 英文名称: 2-methyl-hexahydro-benzo[1,3]dioxole
• 英文别名: 1,3-Benzodioxole, hexahydro-2-methyl-；2-methyl-3a,4,5,6,7,7a-hexahydro-1,3-benzodioxole
• CAS: 61335-43-1
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: FSTBEOFRCQYUKL-UHFFFAOYSA-N

物化性质

• 沸点：
  196.5±8.0 °C(Predicted)
• 密度：
  0.996±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  乙醚 、 1,2-环己二醇 在 copper(II) bis(trifluoromethanesulfonate) 、 苯 作用下， 以68%的产率得到2-methyl-hexahydro-benzo[1,3]dioxole
  参考文献：
  名称：

  前所未有的铜（I）催化的乙醚与邻二醇和缩酮的光化学反应

  摘要：

  报道了一种新颖的Cu（I）催化的二乙基醚与邻二醇及其缩酮的光化学反应。最显着的特征是在完全中性的条件下，无需使用乙醛即可将1，2-二醇及其缩酮转化为乙醛的缩醛。

  DOI：

  10.1016/j.tetlet.2010.06.080

文献信息

• POLARIZING PLATE PROTECTIVE FILM, POLARIZING PLATE, AND DISPLAY DEVICE
  申请人：FUJIFILM Corporation

  公开号：US20170226317A1

  公开（公告）日：2017-08-10

  A polarizing plate protective film which prevents deterioration of polarization performance in a high temperature, high humidity environment, and a polarizing plate and display device using the film including a compound represented by the following General Formula (I). (X-L n z General Formula (I) X represents a formyl group, a boronic acid group, or a group represented by the following General Formula (I-B) or a group represented by the following General Formula (I-C), where L represents a single bond or divalent linking group, and n represents an integer equal to or greater than 2. When n is 2, Z represents a single bond or a divalent group, and when n≧3, Z represents an n-valent group. R A and R B represent an alkyl group, a cycloalkyl group, an aryl group, or an acyl group. R A and R B may be bonded to each other to form a ring. * represents a bond to be bonded to L.

  一种偏光板保护膜，可防止在高温高湿环境中偏光性能的恶化，以及使用包括下述一般式（I）所代表的化合物的偏光板和显示装置。 （X-L n z 一般式（I） X代表甲酰基、硼酸基或由下述一般式（I-B）所代表的基团或由下述一般式（I-C）所代表的基团，其中L代表单键或二价连接基团，n代表大于或等于2的整数。当n为2时，Z代表单键或二价基团，当n≧3时，Z代表n价基团。 RA和RB代表烷基、环烷基、芳基或酰基。RA和RB可以相互连接形成环。*代表要连接到L的键。
• [EN] NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS<br/>[FR] ARYL IMIDAZOLES ET COMPOSES ASSOCIES, MODULATEURS DE RECEPTEUR C5A
  申请人：NEUROGEN CORP

  公开号：WO2003082829A1

  公开（公告）日：2003-10-09

  The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula (I) where the ring system represented by Formula (A) is a 5 membered heteroaryl ring system, in which x is 0, A is chosen from carbon and heteroatoms nitrogen, oxygen, and sulfur, and E and G are independently carbon or nitrogen, provided that the 5 membered heteroaryl ring system does not contain more than 3 heteroatoms or more than 1 oxygen or sulfur atom, or a 6 membered heteroaryl ring system, in which x is 1, A, B, E, and G are independently chosen from carbon and nitrogen, provided that the 6 membered heteroaryl ring system does not contain more than 3 nitrogen atoms. The remaining variables, Ar1, Ar2, R, R1, R2, R3, R4, R5, R6, y and z are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.

  该发明提供了式（I）中的芳基取代咪唑、吡唑、吡啶和相关化合物，其中由式（A）表示的环系统是一个5成员杂芳基环系统，在该环系统中x为0，A从碳和杂原子氮、氧和硫中选择，E和G分别为碳或氮，前提是5成员杂芳基环系统不含超过3个杂原子或超过1个氧或硫原子，或者是一个6成员杂芳基环系统，在该环系统中x为1，A、B、E和G分别从碳和氮中选择，前提是6成员杂芳基环系统不含超过3个氮原子。其余变量Ar1、Ar2、R、R1、R2、R3、R4、R5、R6、y和z在此处定义。这些化合物是C5a受体的配体。该发明的优选化合物具有高亲和力结合到C5a受体，并且在C5a受体上表现为中性拮抗剂或逆激动剂活性。该发明还涉及包含这些化合物的药物组合物。它进一步涉及使用这些化合物治疗各种炎症和免疫系统疾病。
• Amino methyl imidazoles as C5a receptor modulators
  申请人：Neurogen Corporation

  公开号：US20040082577A1

  公开（公告）日：2004-04-29

  Amino methyl imidazoles of Formula I are provided: 1 wherein R, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. Additionally, this invention provides labeled amino methyl imidazoles compounds, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I的氨甲基咪唑化合物：1其中R，R1，R2，R3，R4，R5和R6的定义如本文所述。此类化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现为中性拮抗剂或逆激动剂活性。本发明还涉及包含此类化合物的制药组合物。此外，本发明还涉及标记的氨甲基咪唑化合物，其可用作C5a受体定位的探针。本发明还提供了使用这类化合物治疗各种炎症、心血管和免疫系统疾病的方法。
• Aryl imidazoles and related compounds as C5a receptor modulators
  申请人：Neurogen Corporation

  公开号：US20040116424A1

  公开（公告）日：2004-06-17

  The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula 1 where the ring system represented by 2 is a 5 membered heteroaryl ring system, in which x is 0, A is chosen from carbon and heteroatoms nitrogen, oxygen, and sulfur, and E and G are independently carbon or nitrogen, provided that the 5 membered heteroaryl ring system does not contain more than 3 heteroatoms or more than 1 oxygen or sulfur atom, or a 6 membered heteroaryl ring system, in which x is 1, A, B, E, and G are independently chosen from carbon and nitrogen, provided that the 6 membered heteroaryl ring system does not contain more than 3 nitrogen atoms. The remaining variables, Ar 1 , Ar 2 , R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , y and z are defined herein Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptos. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.

  本发明提供了Formula1的芳基取代咪唑，吡唑，吡啶并咪唑和相关化合物，其中由2表示的环系统是一个五元杂环芳基环系统，在其中x为0，A选择自碳和杂原子氮，氧和硫，并且E和G独立地为碳或氮，前提是五元杂环芳基环系统不含有超过3个杂原子或超过1个氧或硫原子，或者是一个六元杂环芳基环系统，在其中x为1，A，B，E和G独立地选择自碳和氮，前提是六元杂环芳基环系统不含有超过3个氮原子。其余变量，Ar1，Ar2，R，R1，R2，R3，R4，R5，R6，y和z在此定义。这些化合物是C5a受体的配体。本发明的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现出中和拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物。它还涉及使用这些化合物治疗各种炎症和免疫系统紊乱。
• Amino methyl imidazoles and related compounds as C5a receptor modulators
  申请人：Thurkauf Andrew

  公开号：US20070212297A1

  公开（公告）日：2007-09-13

  Amino methyl imidazoles of Formula I are provided: wherein R, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. Additionally, this invention provides labeled amino methyl imidazoles compounds, which are useful as probes for the localization of C5a receptors.

  提供了式I的氨甲基咪唑：其中R，R1，R2，R3，R4，R5和R6如本文所定义。这些化合物是C5a受体的配体。式I的优选化合物以高亲和力结合C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这种化合物的制药组合物。它还涉及使用这种化合物治疗各种炎症，心血管和免疫系统疾病。此外，本发明提供了标记的氨甲基咪唑化合物，可用作C5a受体定位的探针。